期刊文献+

奥沙拉嗪合成工艺的改进 被引量:1

An Improved Synthetic Process of Osalazine
原文传递
导出
摘要 将9·1g亚硝酸钠在15℃以下滴加到15·3g5-氨基水杨酸(5-ASA)和30mL盐酸组成的混合液中,重氮化反应2h制得中间体5-ASA重氮盐(氯化偶氮水杨酸);然后与0·2mol水杨酸钠在碱性条件下偶合,得到粗品。用水重结晶,得到棕黄色粉状结晶奥沙拉嗪21·2g,即3,3’-偶氮(6-羟基苯甲酸)二钠盐,以5-ASA计收率为61·2%。 9.1 g Sodium nitrite was added dropwise to a mixture composed of 15.3g 5-aminosalicylic acid (5-ASA)and 30mL hydrochloric acid at temperature below 15℃. After diazotization for 2 hours the intermediate diazonium salt (chlorinated azosalicylic acid) was formed l which was coupled with 0. 2tool sodium salicylate under alkaline condition. The crude product was obtained after recrystallization was carried out in water, and 21.2g brown yellow powder of Osalazine, named 3,3'-azobis(6-hydroxybenzoic acid)disodium with 95% purity was given. The total yield was 61.2% (calculated based on 5-aminosalicylic acid).
出处 《精细与专用化学品》 CAS 2006年第6期20-22,共3页 Fine and Specialty Chemicals
关键词 奥沙拉嗪 3 3'-偶氮(6-羟基苯甲酸)二钠盐 5-氨基水杨酸 水杨酸 氯化偶氮水杨酸 Osalazine 3,3' -azobis ( 6-hydroxybenzoic acid) disodium 5-aminosalicylic acid salicylic acid chlori-nated azosalicylic acid
  • 相关文献

参考文献5

二级参考文献48

  • 1[1]Prakash A,Markham A.Oral delayed-release mesalazine:a review of its use in ulcerative colitis and Crohn′s disease.Drugs,1999,57(3):383-408
  • 2[2]Sutherland LR,Roth DE,Beck PL.Alternatives to sulfalazine:a meta-analysis of 5-ASA in the treatment of ulcerative colitis.Inflammatory Bowel Dis,1997,34:65-78
  • 3[3]Sutherland L,Roth D,Beck P et al.The use of oral 5-aminosalicylic acid in the induction of remission in ulcerative colitis.In:The Cochrane Library(database on disk and CD-ROM).Oxford:The Cochrane Collaboration.Update Software,1998(4)
  • 4[4]Sutherland L,Roth D,Beck P et al.The use of oral 5-aminosalicylic acid in the induction of maintenance of remission in ulcerative colitis.In:The Cochrane Library(database on disk and CD-RON).Oxford:The Cochrane Collaboration.Update Software,1998,(4)
  • 5[5]Kruis W,Brandes JW,Schreiber S,et al.Olsalaxine versus mesalazine in the treatment of mild to moderate ulcerative colitis.Aliment Pharmacol Ther,1998,12(8):7607-15
  • 6[6]Stoa-Birketvedt G,Florholmen J.The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.Aliment Pharmacol Ther,1999,13(3):357-61
  • 7[7]Prakash A,Spencer CM.Balsalazide.Drugs,1998,56(1):83-9
  • 8[8]Green JR,Gibson JA,Kerr GD,et al.Maintenance of remission of ulcerative colitis:a comparison between balsalazide 3g daily and mesalamine 1.2g daily over 12 month.ABACUS Investigator Group.Aliment Pharmacol Ther,1998,12(12):1207-16
  • 9[9]Gionchetti P,Rizzello F,Venturi A,et al.Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.Dis Colon Rectum,1998,41(1):93-7
  • 10[10]Safdi M,DeMicco M,Sninsky C,et al.A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.Am J Gastroenterol,1997,92(10):1867-71

共引文献63

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部